



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF)

As of 13 July 2021, the Health Technology Assessment Council (HTAC) has finished the assessment and deliberation on **two-dose Inactivated Polio Vaccine (IPV) versus one-dose IPV for the prevention of poliomyelitis**. The evaluation aims to appraise existing relevant information on (a) responsiveness to disease magnitude, severity, and equity; (b) clinical efficacy and safety; (c) cost-effectiveness; (d) affordability and viability; (e) household financial impact, and (f) Ethical, Legal, Social, and Health Systems (ELSHI) impact.

The HTAC hereby makes public the **recommendation for the inclusion of two-dose IPV** attached in the Evidence Summary with supporting studies informing their recommendation. All comments, inputs and/or appeals may be submitted until **28 July 2021** for consideration of the HTAC through email at hta@doh.gov.ph.

Should you wish to submit hard copies of your submissions, you may drop them off at the 4th floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon Avenue, Quezon City. Appeals shall no longer be entertained after the prescribed deadline.

A handwritten signature in black ink, appearing to read "Anna Melissa S. Guerrero".

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
Head, Health Technology Assessment Unit
Health Regulation Team